PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients.

Gunta, Satya Preetham; O'Keefe, James H; O'Keefe, Evan L; Lavie, Carl J

Gunta, Satya Preetham; O'Keefe, James H; O'Keefe, Evan L; Lavie, Carl J.

Afiliação

Gunta SP; Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, United States of America.
O'Keefe JH; Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, United States of America. Electronic address: jokeefe@saintlukeskc.org.
O'Keefe EL; Tulane Medical Center, New Orleans, LA, United States of America.
Lavie CJ; John Ochsner Heart and Vascular Institute, Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, LA, United States of America.

Prog Cardiovasc Dis ; 79: 12-18, 2023.

Article em En | MEDLINE | ID: mdl-36871887

Assuntos

Anticolesterolemiantes; Inibidores de Hidroximetilglutaril-CoA Redutases; Humanos; Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos; Ezetimiba/efeitos adversos; Inibidores de PCSK9; LDL-Colesterol; Pró-Proteína Convertase 9; Anticolesterolemiantes/efeitos adversos; Colesterol

Palavras-chave

Bempedoic acid; Cardiovascular diseases; Ezetimibe; Lipids; PCSK9 inhibitors; Statins

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Anticolesterolemiantes Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google